Ayala Pharm Financials
Ayala Pharm (ADXS) reported $13K in revenue for fiscal year 2023, down 98.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
An R&D-heavy development model relies on external financing as commercial revenue fades and liquidity tightens.
Between FY2022 and FY2023, revenue collapsed while R&D remained at$24.1M ; spending stayed development-scale despite disappearing sales, leaving little evidence that operations were funded by customers. FY2023 operating cash flow was-$29.5M against$4.9M of cash, so reported activity was not translating into self-funded liquidity and the business remained dependent on financing.
FY2023 gross profit was
External funding supplied
Financial Health Signals
Ayala Pharm does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Ayala Pharm scores -24.76, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($25.7M) relative to total liabilities ($41.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Ayala Pharm passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Ayala Pharm reported a net loss of $48.1M while operations used $29.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Ayala Pharm generated $13K in revenue in fiscal year 2023. This represents a decrease of 98.1% from the prior year.
Ayala Pharm's EBITDA was -$35.9M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 3.9% from the prior year.
Ayala Pharm reported -$48.1M in net income in fiscal year 2023. This represents a decrease of 26.5% from the prior year.
Cash & Balance Sheet
Ayala Pharm held $4.9M in cash as of fiscal year 2023; long-term debt is not reported for that period.
Not reported for fiscal year 2023.
Not reported for fiscal year 2023.
Margins & Returns
Ayala Pharm's gross margin was 0.0% in fiscal year 2023, indicating the percentage of revenue retained after direct costs. This is down 13.0 percentage points from the prior year.
Not shown for fiscal year 2023: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2023: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for fiscal year 2023.
Capital Allocation
Ayala Pharm invested $24.1M in research and development in fiscal year 2023. This represents a decrease of 13.5% from the prior year.
Not reported for fiscal year 2023.
Not reported for fiscal year 2023.
ADXS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $9K+125.0% | $4K-96.2% | $105K+15.4% | $91K+139.5% | $38K-91.7% | $458K |
| Cost of Revenue | N/A | N/A | $9K+125.0% | $4K-96.2% | $105K+15.4% | $91K+139.5% | $38K-89.7% | $368K |
| Gross Profit | N/A | N/A | $0 | $0 | $0 | $0 | $0-100.0% | $90K |
| R&D Expenses | N/A | $5.7M-0.7% | $5.7M-21.2% | $7.3M-4.0% | $7.6M+5.1% | $7.2M+29.0% | $5.6M-25.6% | $7.5M |
| SG&A Expenses | N/A | $1.4M-47.6% | $2.8M-40.0% | $4.6M+113.5% | $2.2M-25.2% | $2.9M+26.8% | $2.3M-6.6% | $2.4M |
| Operating Income | N/A | -$7.1M+16.0% | -$8.5M+28.5% | -$11.9M-22.0% | -$9.7M+3.5% | -$10.1M-28.4% | -$7.9M+20.3% | -$9.8M |
| Income Tax | N/A | $65K-48.8% | $127K+103.0% | -$4.2M-5709.3% | $75K-29.2% | $106K-50.5% | $214K+13.2% | $189K |
| Net Income | N/A | -$7.3M+15.6% | -$8.7M-18.2% | -$7.4M+24.6% | -$9.8M+4.1% | -$10.2M-25.6% | -$8.1M+18.5% | -$10.0M |
| EPS (Diluted) | -$2.96 | -$1.53 | -$1.82 | N/A | -$3.32+5.4% | -$3.51-24.0% | -$2.83 | N/A |
Not reported in any period shown, so not listed: Interest Expense.
ADXS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $16.6M+137.5% | $7.0M-42.5% | $12.2M-42.1% | $21.0M+170.2% | $7.8M-70.0% | $25.9M-13.9% | $30.1M-19.8% | $37.5M |
| Current Assets | $7.5M+65.4% | $4.6M-52.4% | $9.6M-47.7% | $18.3M+472.8% | $3.2M-87.6% | $25.8M-13.6% | $29.8M-12.8% | $34.2M |
| Cash & Equivalents | $4.9M+130.0% | $2.1M-70.0% | $7.1M-58.0% | $16.8M+599.3% | $2.4M-78.5% | $11.2M-44.2% | $20.1M-25.8% | $27.1M |
| Goodwill | $4.5M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $41.0M+210.1% | $13.2M+18.7% | $11.1M-1.6% | $11.3M+27.6% | $8.9M-49.6% | $17.6M+40.0% | $12.6M-0.5% | $12.6M |
| Current Liabilities | $25.0M+193.4% | $8.5M+1.2% | $8.4M-14.3% | $9.8M+58.6% | $6.2M+169.3% | $2.3M+20.8% | $1.9M-19.5% | $2.4M |
| Total Equity | -$24.4M-291.2% | -$6.2M-718.5% | $1.0M-89.6% | $9.7M+980.3% | -$1.1M-113.2% | $8.3M-52.5% | $17.5M-29.5% | $24.9M |
| Retained Earnings | -$197.2M-14.3% | -$172.6M-4.4% | -$165.2M-5.6% | -$156.5M-4.9% | -$149.2M+66.3% | -$443.0M-1.0% | -$438.4M-1.6% | -$431.4M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Debt.
ADXS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.2M-3.2% | -$7.0M+18.5% | -$8.6M-27.0% | -$6.7M+17.5% | -$8.2M+12.5% | -$9.3M-142.4% | -$3.9M+61.4% | -$10.0M |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$66K+14.3% | -$77K |
| Financing Cash Flow | $4.0M+100.0% | $2.0M+266.7% | -$1.2M-105.7% | $21.2M+3547.3% | -$615K-231.4% | $468K+2700.0% | -$18K-140.9% | $44K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
ADXS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | 0.0%0.0pp | 0.0%0.0pp | 0.0%0.0pp | 0.0%0.0pp | 0.0%-19.7pp | 19.7% |
| Operating Margin | N/A | N/A | -94288.9% | -296725.0% | -9261.9% | -11076.9% | -20663.2% | -2149.8% |
| Net Margin | N/A | N/A | -96655.6% | -184025.0% | -9301.9% | -11192.3% | -21336.8% | -2173.1% |
| Return on Equity | N/A | N/A | -862.1%-786.1pp | -76.1% | N/A | -122.2%-75.9pp | -46.2%-6.3pp | -40.0% |
| Return on Assets | N/A | -105.1%-33.5pp | -71.6%-36.5pp | -35.1%+90.7pp | -125.7%-86.4pp | -39.3%-12.3pp | -26.9%-0.4pp | -26.5% |
| Current Ratio | 0.30-0.2x | 0.53-0.6x | 1.13-0.7x | 1.86+1.3x | 0.51-10.7x | 11.19-4.5x | 15.64+1.2x | 14.44 |
| Debt-to-Equity | N/A | N/A | 11.04+9.9x | 1.17 | N/A | 2.11+1.4x | 0.72+0.2x | 0.51 |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$24.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.30), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Ayala Pharm Ranks
Frequently Asked Questions
What is Ayala Pharm's annual revenue?
Ayala Pharm (ADXS) reported $13K in total revenue for fiscal year 2023. This represents a -98.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Ayala Pharm's revenue growing?
Ayala Pharm (ADXS) revenue declined by 98.1% year-over-year, from $692K to $13K in fiscal year 2023.
Is Ayala Pharm profitable?
No, Ayala Pharm (ADXS) reported a net income of -$48.1M in fiscal year 2023.
What is Ayala Pharm's EBITDA?
Ayala Pharm (ADXS) had EBITDA of -$35.9M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
What is Ayala Pharm's gross margin?
Ayala Pharm (ADXS) had a gross margin of 0.0% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.
What is Ayala Pharm's operating cash flow?
Ayala Pharm (ADXS) recorded an outflow of $29.5M in operating cash flow during fiscal year 2023, representing cash used by core business activities.
What are Ayala Pharm's total assets?
Ayala Pharm (ADXS) had $16.6M in total assets as of fiscal year 2023, including both current and long-term assets.
How much does Ayala Pharm spend on research and development?
Ayala Pharm (ADXS) invested $24.1M in research and development during fiscal year 2023.
What is Ayala Pharm's current ratio?
Ayala Pharm (ADXS) had a current ratio of 0.30 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.
What is Ayala Pharm's return on assets (ROA)?
Ayala Pharm (ADXS) had a return on assets of -290.0% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
How does Ayala Pharm's liquidity compare with its operating cash outflow?
At the end of fiscal year 2023, Ayala Pharm (ADXS) held $4.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $29.5M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Ayala Pharm's debt-to-equity ratio negative or not reported?
Ayala Pharm (ADXS) has negative shareholder equity of -$24.4M as of fiscal year 2023, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Ayala Pharm's Altman Z-Score?
Ayala Pharm (ADXS) has an Altman Z-Score of -24.76, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Ayala Pharm's Piotroski F-Score?
Ayala Pharm (ADXS) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ayala Pharm's earnings high quality?
Ayala Pharm (ADXS) reported a net loss of $48.1M while operations used $29.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.